Spruce Biosciences Inc. has announced the completion of a $50 million private placement financing backed by dedicated healthcare investors. As part of the transaction, the company entered into a definitive securities purchase agreement in October 2025, issuing 502,181 shares of common stock and prefunded warrants to purchase up to 233,144 shares of common stock. The prefunded warrants are exercisable for five years from the date of issuance. The proceeds from this financing are intended to support the continued advancement of Spruce Biosciences' therapeutic programs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-274216), on November 10, 2025, and is solely responsible for the information contained therein.